Funded Projects › HORIZON
CUREMAL · Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins
CUREMAL project aims to address the urgent need for new malaria treatments due to the increasing resistance to current therapies. Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it causes the majority of malaria-related deaths. The project focuses on developing GSK701, a novel antimalarial compound with a unique mechanism of action, showing no cross-resistance with existing drugs and potential for a single-dose cure.The partners will conduct two clinical trials to evaluate the safety, efficacy, and pharmacokinetics of GSK701 in combination with pyronaridine. These trials will be carried out in malaria-endemic regions from Gabon, Tanzania, Uganda and Mozambique, targeting vulnerable populations, including children and adolescents. The trials will also involve detailed molecular surveillance to understand the effectiveness of the new treatment and monitor resistance patterns.Key objectives include assessing the safety and tolerability of various dosing regimens, evaluating the pharmacokinetic/pharmacodynamic relationship, and identifying genetic variants associated with resistance. The project will also focus on building capacity in African research centres for conducting clinical trials and genetic surveillance. The expected outcomes include progressing GSK701 through development stages, enhancing molecular surveillance of antimalarial resistance, and fostering global and intra-African collaborations. The project aims to contribute to malaria control and elimination efforts, improve treatment adherence with simplified regimens, and support the achievement of the 2030 Sustainable Development Goals related to health.By leveraging multidisciplinary expertise, cutting-edge technology and partners´ in-kind resources, CUREMAL seeks to make a significant impact on public health, providing a robust solution to the growing challenge of antimalarial resistance and advancing towards the ultimate goal of malaria eradication.
Consortium · 11 organisations
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
ES
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
UK
FUNDACAO MANHICA
MZ · €390,254
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
ES · €1,409,688
THE REGISTERED TRUSTEES OF THE IFAKARA HEALTH INSTITUTE
TZ · €1,569,232
MMV MEDICINES FOR MALARIA VENTURE
CH
INFECTIOUS DISEASES RESEARCH COLLABORATION LTD BY GUARANTEE
UG · €1,689,435
HOSPITAL CLINIC DE BARCELONA
ES
EBERHARD KARLS UNIVERSITAET TUEBINGEN
DE · €207,295
Centre de Recherches Medicales de Lambaréné
GA · €2,008,650
STELLENBOSCH UNIVERSITY
ZA · €1,142,741
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.